SCHEDULE 13G/A: Hudson Bay Capital Discloses 4.99% Passive Stake in Aptevo Therapeutics
Beneficial Ownership Disclosure
Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, disclosing a 4.99% passive beneficial ownership stake in Aptevo Therapeutics Inc., including shares issuable from warrants.
Summary
- Hudson Bay Capital Management LP and Sander Gerber collectively hold beneficial ownership of 76,598 shares of Aptevo Therapeutics Inc. common stock.
- This ownership represents 4.99% of Aptevo Therapeutics' outstanding common stock.
- The reported shares include 76,598 shares of Common Stock that are issuable upon the exercise of warrants.
- The percentage is calculated based on 1,458,443 shares of common stock outstanding as of December 16, 2024, as reported in Aptevo's Form S-3 filing on December 20, 2024.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating that reporting person information was inadvertently omitted from a previous filing.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Aptevo Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of a passive ownership stake, providing neutral information regarding the company's operational or financial performance.
Positives
- An institutional investor, Hudson Bay Capital Management LP, holds a significant passive stake, which may signal confidence in the company's long-term prospects.
- The inclusion of warrants in the beneficial ownership indicates a potential future commitment to the company's equity.
Future Outlook
The document does not provide any forward-looking statements or guidance from Aptevo Therapeutics Inc. as it is a beneficial ownership disclosure by an external entity.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure of a passive investment stake by an institutional investor in a biotechnology company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders are informed of a significant passive stake held by an institutional investor, which can contribute to market transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2024-12-16 | Date as of which 1,458,443 shares of Aptevo Therapeutics Inc. common stock were reported outstanding, used for percentage calculation. |
| 2024-12-20 | Date Aptevo Therapeutics Inc. filed its Registration Statement on Form S-3 with the SEC. |
| 2024-12-31 | Date of event which required the filing of this statement. |
| 2025-02-10 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Aptevo Therapeutics Inc., Hudson Bay Capital Management LP, Sander Gerber, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.